- Select a language for the TTS:
- UK English Female
- UK English Male
- US English Female
- US English Male
- Australian Female
- Australian Male
- Language selected: (auto detect) - EN
Play all audios:
Roche on Wednesday said a two-drug combination that includes a novel but still experimental checkpoint-blocking immunotherapy significantly delayed tumor progression in a mid-stage study of
non-small cell lung cancer patients. Reaction to the results might be muted, however, because the new combination treatment — tiragolumab plus Tecentriq — only showed a meaningful benefit in
a subset of lung cancer patients. That profile makes it unlikely to compete against Merck’s dominant Keytruda-chemotherapy combination. Roche announced the full study results to coincide
with the release of a research abstract for the annual meeting of the American Society of Clinical Oncology (ASCO). STAT+ Exclusive Story Already have an account? Log in THIS ARTICLE IS
EXCLUSIVE TO STAT+ SUBSCRIBERS UNLOCK THIS ARTICLE — PLUS DAILY COVERAGE AND ANALYSIS OF THE BIOTECH SECTOR — BY SUBSCRIBING TO STAT+. Already have an account? Log in Individual plans Group
plans View All Plans To read the rest of this story subscribe to STAT+. Subscribe
